From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

被引：92

作者：

Lu, Hui ^{[1
]}

Zhao, Xiaoyan ^{[1
]}

Li, Ziying ^{[1
]}

Hu, Yu ^{[1
]}

Wang, Huafang ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

基金：

中国国家自然科学基金;

关键词：

chimeric antigen receptor; natural killer cells; T cells; immunotherapy; hematological malignancies; NATURAL-KILLER-CELLS; CHIMERIC-ANTIGEN-RECEPTOR; CLINICAL-TRIAL; NK-92; CELLS; CELLULAR IMMUNOTHERAPY; MYELOID MALIGNANCIES; VIVO EXPANSION; MESSENGER-RNA; STEM-CELLS; PHASE-II;

D O I：

10.3389/fonc.2021.720501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However, the remaining limitations concerning the graft-versus-host disease (GVHD) and other adverse effects (e.g., cytokine release syndromes [CRS] and neurotoxicity) still restrict their wider applications. Natural killer (NK) cells have been identified as promising candidates for CAR-based cellular immunotherapy because of their unique characteristics. No HLA-matching restriction and abundant sources make CAR-engineered NK (CAR-NK) cells potentially available to be off-the-shelf products that could be readily available for immediate clinical use. Therefore, researchers have gradually shifted their focus from CAR-T cells to CAR-NK cells in hematological malignancies. This review discusses the current status and applications of CAR-NK cells in hematological malignancies, as well as the unique advantages of CAR-NK cells compared with CAR-T cells. It also discusses challenges and prospects regarding clinical applications of CAR-NK cells.

引用

页数：13

共 128 条

[71] Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity [J].

Liu, E. ;

Tong, Y. ;

Dotti, G. ;

Shaim, H. ;

Savoldo, B. ;

Mukherjee, M. ;

Orange, J. ;

Wan, X. ;

Lu, X. ;

Reynolds, A. ;

Gagea, M. ;

Banerjee, P. ;

Cai, R. ;

Bdaiwi, M. H. ;

Basar, R. ;

Muftuoglu, M. ;

Li, L. ;

Marin, D. ;

Wierda, W. ;

Keating, M. ;

Champlin, R. ;

Shpall, E. ;

Rezvani, K. .

LEUKEMIA, 2018, 32 (02) :520-531

[72] Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors [J].

Liu, Enli ;

Marin, David ;

Banerjee, Pinaki ;

Macapinlac, Homer A. ;

Thompson, Philip ;

Basar, Rafet ;

Kerbauy, Lucila Nassif ;

Overman, Bethany ;

Thall, Peter ;

Kaplan, Mecit ;

Nandivada, Vandana ;

Kaur, Indresh ;

Cortes, Ana Nunez ;

Cao, Kai ;

Daher, May ;

Hosing, Chitra ;

Cohen, Evan N. ;

Kebriaei, Partow ;

Mehta, Rohtesh ;

Neelapu, Sattva ;

Nieto, Yago ;

Wang, Michael ;

Wierda, William ;

Keating, Michael ;

Champlin, Richard ;

Shpall, Elizabeth J. ;

Rezvani, Katayoun .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06) :545-553

[73] Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model [J].

Liu, Qian ;

Xu, Yingxi ;

Mou, Junli ;

Tang, Kejing ;

Fu, Xuehang ;

Li, Yihui ;

Xing, Yanyan ;

Rao, Qing ;

Xing, Haiyan ;

Tian, Zheng ;

Wang, Min ;

Wang, Jianxiang .

CYTOTHERAPY, 2020, 22 (10) :552-562

[74] IN SEARCH OF THE MISSING SELF - MHC MOLECULES AND NK CELL RECOGNITION [J].

LJUNGGREN, HG ;

KARRE, K .

IMMUNOLOGY TODAY, 1990, 11 (07) :237-244

[75] The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation [J].

Luevano, Martha ;

Daryouzeh, Mehri ;

Alnabhan, Rehab ;

Querol, Sergio ;

Khakoo, Salim ;

Madrigal, Alejandro ;

Saudemont, Aurore .

HUMAN IMMUNOLOGY, 2012, 73 (03) :248-257

[76] Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch [J].

Ma, Gina ;

Shen, Jiaqi ;

Pinz, Kevin ;

Wada, Masayuki ;

Park, Jino ;

Kim, Soojin ;

Togano, Tomiteru ;

Tse, William .

STEM CELL REVIEWS AND REPORTS, 2019, 15 (03) :443-447

[77] Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92 [J].

Maki, G ;

Klingemann, HG ;

Martinson, JA ;

Tam, YK .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (03) :369-383

[78] A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies [J].

Mamonkin, Maksim ;

Rouce, Rayne H. ;

Tashiro, Haruko ;

Brenner, Malcolm K. .

BLOOD, 2015, 126 (08) :983-992

[79] Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors [J].

Melaiu, Ombretta ;

Lucarini, Valeria ;

Cifaldi, Loredana ;

Fruci, Doriana .

FRONTIERS IN IMMUNOLOGY, 2020, 10

[80] Recovery and safety profiles of marrow and PBSC donors: Experience of the National Marrow Donor Program [J].

Miller, John P. ;

Perry, Elizabeth H. ;

Price, Thomas H. ;

Bolan, Charles D., Jr. ;

Karanes, Chatchada ;

Boyd, Theresa M. ;

Chitphakdithai, Pintip ;

King, Roberta J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) :29-36

← 3 4 5 6 7 8 9 10 11 12 →